Centers | ||
Therapeutic Accelerator Program (TAP) | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | VMCC, University of Michigan |
Test |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
The VMCC is an on-campus core facility for the design and synthesis of drug-like molecules and diagnostic probes used in biomedical investigations. Our Mission: To assist biomedical researchers in translating novel therapeutic hypotheses into... |
Partnerships |
Events |
Jobs |
Vanderbilt and Astra Zeneca to Develop New Drugs to Treat Psychosis and Other Brain DisordersUnder a new research collaboration agreement, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Astra Zeneca will work together to develop compounds that act on M4 muscarinic acetylcholine receptor. The agreement entails research... View all Eisiai Partners with Johns Hopkins Brain Science InstituteEisiai Partners with Johns Hopkins Brain Science Institute ("BSi") an institute which is part of Johns Hopkins University to develop new drugs for neurological diseases. Under this joint collaboration, BSi will provide validated targets to Eisai... View all Research collaboration and license agreementThe University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon... View all |
No EVENTS for listing |
No Job Posts |


